Limitations of the Fasting Glucose to Insulin Ratio as an Index of Insulin Sensitivity

Michael J. Quon

Cardiology Branch National Heart, Lung, and Blood Institute National Institutes of Health Bethesda, Maryland 20892

Address all correspondence and requests for reprints to: Michael J. Quon, M.D., Ph.D., Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Building 10, Room 8C-218, 10 Center Drive MSC 1755, Bethesda, Maryland 20892-1755. E-mail: quonm{at}nih.gov

Biological actions of insulin are essential for regulation and maintenance of glucose homeostasis. Insulin resistance (typically defined as decreased sensitivity or responsiveness to the metabolic actions of insulin) plays an important role in the pathophysiology of diabetes (1, 2). Insulin resistance is also associated with obesity (3) as well as hypertension, coronary artery disease, and dyslipidemias (4). Moreover, insulin resistance is a feature of a number of syndromes related to abnormal reproductive endocrinology, such as polycystic ovarian syndrome (5) and premature adrenarche (6, 7). Therefore, it is of great interest to quantify insulin sensitivity and resistance in humans to investigate the pathophysiology and epidemiology of major public health problems and to follow the clinical course of patients on various therapeutic regimens.

A host of methods have been developed to assess insulin sensitivity and insulin resistance in vivo. These include the hyperinsulinemic euglycemic glucose clamp technique (8), minimal model analysis of a frequently sampled iv glucose tolerance test (FSIVGTT) (9), and various indices derived from an oral glucose tolerance test (10, 11) or fasting glucose and insulin values (12, 13, 14, 15, 16). A number of variations on each of these approaches are available. For example, the glucose clamp technique can be performed under euglycemic, isoglycemic, or hyperglycemic conditions with or without infusion of tracer-labeled glucose (17). Likewise, minimal model analysis has been extended to analyze FSIVGTT modified by exogenous tolbutamide or insulin infusion (18) with or without infusion of tracer-labeled glucose (19).

The glucose clamp is generally regarded as the reference method for assessing insulin sensitivity in humans because it directly measures metabolic actions of insulin under steady state conditions. However, the clamp is also the most complicated method to implement because it requires simultaneous infusions of insulin, glucose, and potassium, multiple blood draws, and an experienced operator to adjust the glucose infusion appropriately over a 3- to 6-h time period. Minimal model analysis of an FSIVGTT is simpler to implement than the glucose clamp but still requires iv administration of glucose and insulin and multiple blood draws over a 3-h time course. Although minimal model results generally correlate with clamp measurements, identification of the minimal model index of insulin sensitivity in subjects with impaired insulin secretion (e.g. patients with diabetes) is problematic (15, 20). Moreover, there are systematic errors in minimal model estimates of glucose effectiveness and insulin sensitivity that may be due to oversimplified model representations of physiology (21, 22, 23). Simple indices of insulin sensitivity based on fasting glucose and insulin levels such as homeostasis model assessment (HOMA) (12) and QUICKI (15) are easily obtained and may be useful tools for large epidemiological studies. As discussed in a scholarly review on measurement of insulin sensitivity by Radziuk (25) in JCEM, the choice of an appropriate method to measure insulin sensitivity depends, in part, on the relative merits of each method for a particular application.

Recently, a number of studies have suggested that the fasting glucose to insulin ratio (G/I) may represent another useful method for assessing insulin resistance (13, 26, 27). However, unlike HOMA or QUICKI, which are based on the product of fasting insulin and glucose (12, 15, 28), G/I does not appropriately reflect the physiology underlying the determinants of insulin sensitivity. This issue has been nicely discussed in the context of the dynamics of an oral glucose tolerance test in a recent paper by Matsuda and DeFronzo (11). Similar arguments also apply to the G/I index obtained under fasting steady state conditions. In normal subjects who are fasting, glucose homeostatic mechanisms involving regulation of both hepatic glucose production and insulin secretion by pancreatic ß cells maintain glucose in the normal range. Under these steady state conditions elevations in fasting insulin levels (in the context of normal fasting glucose levels) correspond to increased insulin resistance. Indeed, in nondiabetic subjects, 1/(fasting insulin) is a well known proxy for insulin sensitivity that decreases as subjects become more insulin resistant (and fasting insulin levels rise) (29, 30, 31, 32, 33, 34). In the case of nondiabetic subjects, G/I is functionally equivalent to 1/insulin since the fasting glucose levels are similar for all subjects. This is the reason that the G/I ratio correlates with insulin sensitivity in nondiabetic patients with polycystic ovarian syndrome (13) or premature adrenarche (26, 27). Not surprisingly, in the paper by Vuguin et al. (26), a comparable correlation was observed when either the fasting insulin or G/I was compared with the minimal model index of insulin sensitivity.

The potential problems with using the fasting G/I ratio as a physiologically appropriate index of insulin sensitivity become apparent when fasting glucose levels are abnormal. This is easily illustrated by comparing a normal subject with an insulin-resistant nondiabetic subject and an insulin-resistant subject with type 2 diabetes (Table 1Go). As explained above, when a normal subject is compared with a nondiabetic insulin-resistant subject (whose fasting insulin level is elevated), simple indices of insulin sensitivity based on fasting values such as 1/insulin, QUICKI, and G/I are all decreased in the insulin-resistant subject when compared with the normal subject, just as expected. Likewise, HOMA, an index of insulin resistance, increases as expected. A diabetic subject who has the same fasting insulin level as the nondiabetic insulin-resistant subject is obviously even more insulin resistant because the same level of insulinemia is not able to appropriately compensate for fasting hyperglycemia. Importantly, in this diabetic subject, the value for QUICKI is decreased even further and HOMA is increased further, exactly as one might predict. However, 1/insulin remains unchanged between the diabetic subject and the nondiabetic insulin-resistant subject, and G/I paradoxically and erroneously increases in the diabetic subject. Thus, QUICKI and HOMA both behave qualitatively as expected across a broad spectrum of insulin sensitivity and resistance. By contrast, the G/I ratio and 1/insulin only behave appropriately in subjects with normal fasting glucose. Indeed, G/I is functionally equivalent to 1/insulin under these conditions, and there is no advantage to using G/I instead of 1/insulin. Because the fasting G/I ratio as an index of insulin sensitivity is conceptually inappropriate, the use of 1/insulin in nondiabetic subjects would be preferable. Moreover, it has previously been shown that QUICKI is a superior index of insulin sensitivity relative to the minimal model index or HOMA (15, 28).


View this table:
[in this window]
[in a new window]
 
Table 1. Comparison of various indices of insulin sensitivity and insulin resistance derived from fasting insulin and glucose levels in normal, insulin-resistant, and diabetic subjects

 
In summary, the fasting G/I ratio is a potentially flawed index of insulin sensitivity whose test characteristics are likely to be similar to 1/insulin in nondiabetic subjects. More robust and accurate simple indices of insulin sensitivity such as QUICKI and log[HOMA] would appear to have greater clinical utility.

Acknowledgments

Footnotes

Abbreviations: FSIVGTT, Frequently sampled iv glucose tolerance test; G/I, glucose to insulin ratio; HOMA, homeostasis model assessment; QUICKI, quantitative insulin-sensitivity check index.

Received April 25, 2001.

Accepted June 6, 2001.

References

  1. DeFronzo RA, Bonadonna RC, Ferrannini E 1992 Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15:318–368[Abstract]
  2. Reaven GM 1993 Role of insulin resistance in the pathophysiology of non-insulin dependent diabetes mellitus. Diabetes Metab Rev 9(Suppl 1):5S–12S
  3. Kahn SE, Prigeon RL, Schwartz RS, et al. 2001 Obesity, body fat distribution, insulin sensitivity and Islet beta-cell function as explanations for metabolic diversity. J Nutr 131:354S–360S
  4. McFarlane SI, Banerji M, Sowers JR 2001 Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 86:713–718[Free Full Text]
  5. Dunaif A, Thomas A 2001 Current concepts in the polycystic ovary syndrome. Annu Rev Med 52:401–419[CrossRef][Medline]
  6. Oppenheimer E, Linder B, DiMartino-Nardi J 1995 Decreased insulin sensitivity in prepubertal girls with premature adrenarche and acanthosis nigricans. J Clin Endocrinol Metab 80:614–618[Abstract]
  7. Dimartino-Nardi J 1999 Premature adrenarche: findings in prepubertal African-American and Caribbean-Hispanic girls. Acta Paediatr Suppl 88:67–72[Medline]
  8. DeFronzo RA, Tobin JD, Andres R 1979 Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214–E223
  9. Bergman RN, Prager R, Volund A, Olefsky JM 1987 Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 79:790–800[Medline]
  10. Belfiore F, Iannello S, Volpicelli G 1998 Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels. Mol Genet Metab 63:134–141[CrossRef][Medline]
  11. Matsuda M, DeFronzo RA 1999 Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470[Abstract]
  12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419[Medline]
  13. Legro RS, Finegood D, Dunaif A 1998 A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 83:2694–2698[Abstract/Free Full Text]
  14. Raynaud E, Perez-Martin A, Brun JF, Benhaddad AA, Mercier J 1999 Revised concept for the estimation of insulin sensitivity from a single sample. Diabetes Care 22:1003–1004[Free Full Text]
  15. Katz A, Nambi SS, Mather K, et al. 2000 Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85:2402–2410[Abstract/Free Full Text]
  16. McAuley KA, Williams SM, Mann JI, et al. 2001 Diagnosing insulin resistance in the general population. Diabetes Care 24:460–464[Abstract/Free Full Text]
  17. Ferrannini E, Mari A 1998 How to measure insulin sensitivity. J Hypertens 16:895–906[CrossRef][Medline]
  18. Saad MF, Steil GM, Kades WW, et al. 1997 Differences between the tolbutamide-boosted and the insulin-modified minimal model protocols. Diabetes 46:1167–1171[Abstract]
  19. Vicini P, Caumo A, Cobelli C 1997 The hot IVGTT two-compartment minimal model: indexes of glucose effectiveness and insulin sensitivity. Am J Physiol 273:E1024–E1032
  20. Saad MF, Anderson RL, Laws A, et al. 1994 A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Insulin Resistance Atherosclerosis Study. Diabetes 43:1114–1121[Abstract]
  21. Quon MJ, Cochran C, Taylor SI, Eastman RC 1994 Non-insulin-mediated glucose disappearance in subjects with IDDM. Discordance between experimental results and minimal model analysis. Diabetes 43:890–896[Abstract]
  22. Cobelli C, Bettini F, Caumo A, Quon MJ 1998 Overestimation of minimal model glucose effectiveness in presence of insulin response is due to undermodeling. Am J Physiol 275:E1031–E1036
  23. Finegood DT, Tzur D 1996 Reduced glucose effectiveness associated with reuced insulin release: an artifact of the minimal-model method. Am J Physiol 271:E485–E495
  24. Deleted in proof
  25. Radziuk J 2000 Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab 85:4426–4433[Abstract/Free Full Text]
  26. Vuguin P, Saenger P, DiMartino-Nardi J 2001 Fasting glucose insulin ratio: a useful measure of insulin resistance in girls with premature adrenarche. J Clin Endocrinol Metab 86:4618–4621[Abstract/Free Full Text]
  27. Silfen ME, Manibo AM, McMahon DJ, Levine LS, Murphy AR, Oberfield SE Fasting glucose to insulin ratio is a simple and useful measure of insulin resistance in young girls with premature adrenarche or obesity. J Clin Endocrinol Metab 86:2863–2868
  28. Bastard JP, Robert JJ, Jardel C, Bruckert E, Grimaldi A, Hainque B 2001 Is quantitative insulin sensitivity check index, a fair insulin sensitivity index in humans? Diabetes Metab 27:69–70[Medline]
  29. Laakso M 1993 How good a marker is insulin level for insulin resistance? Am J Epidemiol 137:959–965[Abstract]
  30. Mykkanen L, Haffner SM, Ronnemaa T, Watanabe RM, Laakso M 1996 Relationship of plasma insulin concentration and insulin sensitivity to blood pressure. Is it modified by obesity? J Hypertens 14:399–405[Medline]
  31. Haffner SM 1998 Epidemiology of type 2 diabetes: risk factors. Diabetes Care 21(Suppl 3):C3–C6
  32. Haffner SM, Miettinen H, Stern MP 1997 The homeostasis model in the San Antonio Heart Study. Diabetes Care 20:1087–1092[Abstract]
  33. Boyko EJ, Leonetti DL, Bergstrom RW, Newell-Morris L, Fujimoto WY 1996 Low insulin secretion and high fasting insulin and C-peptide levels predict increased visceral adiposity. 5-year follow-up among initially nondiabetic Japanese-American men. Diabetes 45:1010–1015[Abstract]
  34. Odeleye OE, de Courten M, Pettitt DJ, Ravussin E 1997 Fasting hyperinsulinemia is a predictor of increased body weight gain and obesity in Pima Indian children. Diabetes 46:1341- 1345[Abstract]